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1. Introduction
1.1. Melanoma a growing problem
The U.S. National Cancer Institute’s Surveillance Epidemiology and End Results (SEER)
Cancer Statistics Review estimates over 70,000 people will be diagnosed and 9,000 will die
from melanoma in the United States in 2012. Though melanoma can affect persons of essen‐
tially any age, it is mainly a disease of adulthood, with median ages of diagnosis and death
between 61 and 68 years, respectively (Weinstock, 2012). Nonetheless, melanoma incidence is
increasing across age groups, over the past several decades in the United States (Fig. 1)
(Ekwueme et al., 2011). In 1935, the average American individual had a 1 in 1,500 lifetime risk
of developing melanoma. In 2002, the approximate risk of developing melanoma increased to
1 in 68 individuals (Rigel, 2002). Globally, Australia and New Zealand have the highest
incidence rate of melanoma, an abundance of fair-skinned residents living in a UV-rich
geography widely believed to be a major factor (Lens and Dawes, 2004). The current melanoma
risk for Australian and New Zealander populations may be as high as 1 in 50 (Rigel, 2010).
Considering melanoma is being diagnosed more often in young adults, could be prevented by
UV-avoiding behaviors, and can be associated with extensive morbidity and mortality, it is
truly an emerging public health concern. Part of the apparent increase in melanoma incidence
may be due to better surveillance and earlier detection (Erdmann et al., 2012) however, even
with heightened melanoma awareness and screening, there seems to have been a real increase
in melanoma incidence over the past several decades.
1.2. The ultraviolet connection
Historically, humans have been exposed to UV radiation primarily as a consequence of
unprotected exposure to sunlight (Holman et al., 1983; Holman et al., 1986;Woodward and
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Boffetta, 1997). Since the early 20th century, a tanned appearance has been culturally associated
with health and well-being in Western civilizations. The desire to sport a dark tan has been
matched by increased opportunities for sunbathing outdoors as well as proliferation of indoor
tanning salons. UV radiation has many deleterious effects on cells (Zaidi et al., 2012), producing
both direct and indirect DNA damage, resulting in mutations that can contributed to carcino‐
genesis in skin cells. Direct damage occurs when DNA absorbs UV photons and undergoes
cleavage of the 5-6 double bond of pyrimidines. When two adjacent pyrimidines undergo this
5-6 double bond opening, a covalent ring structure referred to as a cyclobutane pyrimidine
dimer (thymine dimer) can be formed. Alternatively, a pyrimidine 6-4 pyrimidone (6,4)-
photoproduct can result when a 5-6 double bond in a pyrimidine opens and reacts with the
exocyclic moiety of the adjacent 3' pyrimidine to form a covalent 6-4 linkage (Kadekaro et al.,
2003; Pfeifer et al., 2005; Maddodi and Setaluri, 2008). Both (6,4)-photoproducts and cyclobu‐
tane dimers can result in characteristic transition mutations between adjacent pyrimidines.
“UV signature mutations” involving T-to-C or C-to-T changes are a common feature of UV-
induced malignancies such as skin cancers (Kanjilal et al., 1993; Nataraj et al., 1996; Soehnge
et al., 1997; Sarasin, 1999). UV radiation also damages cellular macromolecules indirectly,
through production of oxidative free radicals [20]. Several DNA modifications can result from
oxidative injury, including 7,8-dihydro-8-oxoguanine (8-oxoguanine; 8-OH-dG), which
promotes mutagenesis (specifically GC-TA transversion mutations) (Kino and Sugiyama,
2005). Both direct and indirect DNA changes interfere with transcription and replication, and
render skin cells susceptible to mutagenesis. It is estimated that one day’s worth of sun
exposure can cause up to 100,000 potentially mutagenic UV-induced photolesions in each skin
cell (Nakabeppu et al., 2006).
Figure 1. Increasing incidence of melanoma of the skin, US. Data are reported as lifetime risk and are taken from
NCI SEER reports.
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Much of solar UV energy is absorbed by stratospheric ozone, and gradual depletion of
stratospheric ozone over the last several decades has resulted in higher levels of solar UV
radiation striking Earth’s surface (van der Leun et al., 2008). Increased ambient UV radiation
from global climate change may be an important factor to explain the burgeoning prevalence
of melanoma (Schmalwieser et al., 2005). Increased exposure to ambient UV radiation is a
feature of global climate change because of thinning of atmospheric ozone and increased
outdoor occupational and recreational activities associated with a warming climate (de Gruijl
et al., 2003; van der Leun et al., 2008; Andrady et al., 2010; Makin, 2011; McKenzie et al., 2011;
Norval et al., 2011). UV exposure in youth seems particularly important, affording the longest
amount of time for the gradual accumulation of mutagenic UV lesions. Thus, high UV
exposures in childhood, adolescence and young adulthood are strongly linked to risk of skin
cancer later in life. For example, first exposure to indoor tanning before the age of 35 years
raises lifetime risk of melanoma by seventy five percent (Schulman and Fisher, 2009).
1.3. Geographic location
UV radiation varies with altitude and with proximity to the equator. Since UV radiation can
be absorbed, reflected back into space or scattered by particles in the atmosphere, ambient UV
doses on the surface of the Earth vary according to the amount of atmosphere solar radiation
must pass through. The more atmosphere solar radiation passing through, the weaker the
corresponding UV content of the sunlight realized on the surface of the Earth. Sunlight strikes
Earth most directly at the equator and more tangentially toward the poles. The more direct the
sunlight’s path, the less atmosphere radiation has to traverse and the more powerful the UV
component will be (Fig. 2). Thus, UV content of sunlight is most powerful in equatorial
locations and weakest in polar extremes. Equatorial locations are also typically the hottest
environments, therefore people living in such places tend to wear lesser amounts of clothing.
Fabrics and other materials used for clothing typically block large amounts of UV radiation,
as evidenced by the pattern of “farmer tans” among people who wear short sleeve tee shirts.
Persons living in cold, polar climates would be expected to realize far less UV radiation from
sunlight both because the UV dosage in ambient sunlight is weaker in such locations and
because people living there probably are covered with more clothing. Thus in general,
individuals living in equatorial locations typically receive much higher ambient UV doses than
persons inhabiting temperate climates (Lee and Scotto, 1993). In the United States, risk of
melanoma is higher in the South than in the North (Crombie, 1979). Worldwide, melanoma
rates are highest in UV-rich environments such as Australia (Franceschi and Cristofolini,
1992; Elwood and Koh, 1994; Marks, 1995). One study examining the low rates of melanoma
in Scandinavia pointed to data showing that ambient UV levels in Norway were significantly
lower than most of the world because of its high latitude (Moan et al., 2009). Altitude and the
amount of particulate matter in the atmosphere also influence the amount of UV found in a
particular geographic location. The higher the altitude, the nearer the location to the sun and
the more powerful the sunlight’s UV dose will be. Similarly, the more particles in the atmos‐
phere, the higher the likelihood of interference with UV and the weaker the UV energy at the
earth’s surface (Atkinson et al., 2011).
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Figure 2. Strength of ambient UV varies with geographic location. UV radiation in sunlight can be blocked by the
atmosphere. Consequently, the longer the distance sunlight must travel, the weaker the UV component hitting Earth
will be. The highest UV doses in sunlight are found at the equator, where the sun hits the Earth at a direct angle.
2. Risk factors
2.1. Older age
Melanoma incidence increases markedly with advancing age (Fig. 3), presumably because of
the time it takes to accumulate mutations in melanocyte-relevant genes that drive carcinogen‐
esis (Gilchrest et al., 1999). However other factors may also be relevant, including a more
permissive environment for tumors to develop because of the natural age-related decline in
cellular immunity (Weiskopf et al., 2009; Malaguarnera et al., 2010). According to the SEER
data, from 2005-2009, the median age of melanoma diagnosis was 61 years. Nonetheless,
although older adults are more at risk for melanoma, the incidence of melanoma in young
adults, especially in young adult women, is increasing at a faster rate (Reed et al., 2012). For
women and men between the ages of 20-29, melanoma is the second and third most commonly
diagnosed cancer respectively (Siegel et al., 2012).
2.2. Solar UV exposure
Decreasing UV radiation exposure, from both sun exposure and artificial UV light, may be the
single best preventable factor for decreasing the incidence rate of melanoma (Lucas et al.,
Recent Advances in the Biology, Therapy and Management of Melanoma6
2008). The ultraviolet portion of sunlight is divided into UVC (<280 nm), UVB (280-315 nm)
and UVA (315-400 nm), with wavelengths below 290 nm being absorbed by stratospheric
ozone (Fig. 4). UVB constitutes 5 -10% of solar UV irradiation and is mainly absorbed by the
epidermal layer of the skin. The most frequent form of DNA damage induced by UVB are
molecular rearrangements resulting in the dimerization of pyrimidines, generating 2 classes
of mutagenic lesions, cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone
photoproducts (6-4 PP) through direct absorption by DNA. CPDs are formed through a ring
structure involving C5 and C6 of neighboring bases whereas 6-4 PP are formed with a non-
cyclic bond between C6 and C4 (Budiyanto et al., 2002). These photoproducts promote
cytosines (C)- thymines (T) and CC-TT transitions, with regions of DNA containing 5-
methylocytosine being hot spots for UVB-induced mutations. Radiation in UVA range is
associated with lower energy but has the ability to penetrate deeper into the dermis. In contrast
to UVB, UVA is poorly absorbed by DNA, but excites numerous endogenous chromophores,
generating reactive oxygen species (ROS) e.g. singlet oxygen and hydroxyl radicals. The
predominant ROS-induced lesions formed are oxidized bases, such as 8-oxo-dG with DNA
single and double strand breaks (Mouret et al., 2006). Both ultraviolet A radiation (320 to 400
nm) and ultraviolet B radiation (290 to 320 nm) contribute to the development of melanoma
(Gilchrest et al., 1999).
Figure 3. Melanoma incidence by age, US. Incidence rates (per 100,000 individuals) are based on NCI SEER data.
Note the marked increase in melanoma incidence with increasing age. Also evident is the tremendous discrepancy in
melanoma incidence between persons of fair- and dark-skinned complexions.
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Figure 4. Electromagnetic spectrum of visible and UV radiation and biologic effects on the skin. The diagram
shows the subdivision of the solar UV spectrum with the shorter UV wavelengths (i.e. UVC) being entirely absorbed by
stratospheric oxygen, and the majority of UVB (> 90 %) being absorbed by ozone. UV light penetrates the skin and is
absorbed by different layers in a wavelength- dependent manner. The visible and UVA components of solar radiation
penetrates deeply into the dermis reaching the dermal stratum papillare. In contrast, UVB is almost completely absor‐
bed by the epidermis, with only ~20 % reaching the epidermal stratum basale. UVA and visible light make up the ma‐
jority of the total terrestrial solar energy and are able to generate reactive oxygen species that can damage DNA via
indirect photosensitizing reactions. UVB is directly absorbed by DNA which causes molecular rearrangements forming
the specific photoproducts CPD and 6-4 PP. Mutations and cancer can result from a variety of modifications to DNA.
2.3. Sunburns
While squamous cell carcinoma of the skin has been closely associated with long term
occupational exposure to the sun, risk of developing melanoma seems to be more associated
with intermittent, high intensity sun exposure (MacKie and Aitchison, 1982; Lew et al., 1983).
Prevalence of sunburns among children is high, with one study finding that approximately
69% of adolescents experienced sunburn the previous summer and only 40% used sun
protection methods (Buller et al., 2011). Positive association between severe, painful sunburn
and the development of melanoma and a negative association between Early found a positive
melanoma and long-term recreational/occupational sun exposure (MacKie and Aitchison,
1982; Lew et al., 1983). Sunburn represents an inflammatory response of the skin to a significant
amount of acute UV damage. It is mediated by a complex series of cellular and hormonal
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events, including the generation of cytokines and mediators of vasodilatation. Risk of sunburn
is related not only to UV exposure, but also to innate melanin content of the skin. Thus, sunburn
mostly occurs in fair skinned people without sun protection exposed to high intensities of UV
radiation, for example in equatorial or high altitude locations. Various epidemiologic studies
support the finding that the number of severe sunburns and total childhood sun exposure are
positively associated with the development of melanoma (Holman et al., 1986; Scotto and
Fears, 1987; Cust et al., 2011; Newton-Bishop et al., 2011; Volkovova et al., 2012). The carcino‐
genic effects of sunburn have also been demonstrated experimentally using transgenic mice
forcing overexpression of the hepatocyte growth/scatter factor (HGF/SF) in melanocytes. In
these mice, HGF over-expression altered the distribution of melanocytes to create a “human‐
ized” model, which mimics human skin with melanocytes located in the basal layer of the
epidermis, rendering them more susceptible to DNA damaging effects of UVR. Remarkably,
a single erythemal UV dose to neonatal mice caused the development of melanomas in roughly
half of animals at one year of age (Noonan et al., 2001). This animal model has been used by
several laboratories to study a variety of melanoma susceptibility genes in context of UV-
induced childhood sunburn and melanoma initiation and metastasis (Recio et al., 2002).
2.4. Indoor tanning
Whereas only one percent of Americans ever used a tanning bed in 1988, now more than twenty
five percent have participated in indoor tanning. With more than 25,000 facilities in the US
alone, indoor tanning represents a multi-billion dollar industry. Employing over 160,000
people, the tanning industry has a customer base of nearly thirty million people and exerts
political influence through powerful lobbying efforts. Nonetheless, there are clear health risks
associated with indoor tanning. UV radiation emitted by tanning lamps is typically more
powerful than direct ambient sunlight. It is estimated that half an hour in a tanning booth
yields the same UV damage to skin as much as 300 minutes in unprotected sun. Levels of UVA/
UVB emitted by tanning beds are unpredictable, widely unregulated, and much higher than
environmental exposure. A study of 62 tanning salons in North Carolina found that the average
UVA output of a tanning bed was 192.1 W/m2 (vs. average UVA summer solar output at noon
in Washington D.C. of 48 W/m2) and the average UVB output of a tanning bed was 0.35
W/m2 (vs. average UVB summer solar output at noon in Washington D.C. of 0.18 W/m2)
(Hornung et al., 2003). Tanning bed use is clearly associated with skin cancers of all varieties.
Persons who have ever used a tanning bed have a 50% increased risk of basal cell carcinoma
and more than a 100% increased risk of squamous cell carcinoma (Karagas et al., 2002).
The risk association between melanoma development and indoor tanning has been well
substantiated (Autier, 2004; Rados, 2005; Han et al., 2006). Data accumulated from several
studies suggest that the use of a tanning salon before the age of 35 is associated with a 75%
increased lifetime risk of melanoma, while over-use of tanning salons was associated with a
15% increased risk of melanoma (Fig. 5) (Schulman and Fisher, 2009). Risk of carcinogenesis
is enhanced for all types of tanning beds (UVA, UVB and mixed output) and increases with
years of use, number of sessions, and hours exposed (Lazovich et al., 2010). There currently is
no “safe” way to tan by UV without the inherent risk of photodamage and malignancy. The
Melanoma — Epidemiology, Genetics and Risk Factors
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use of tanning salons despite the established risks, however, remains popular, especially in
female young adults and adolescents. A recent survey found that 18.1% of female and 6.3% of
male Caucasian adults reported using a tanning salon in the past 12 months (Choi et al.,
2010). Among 10,000 adolescents across the 50 states, 24.6% of girls under 18 reported tanning,
with prevalence of use steadily increasing from age 12 to 18 years (Geller et al., 2002). California
and Vermont have recently banned (January 2012 and July 2012 respectively) use of indoor
tanning beds for minors, while many other states require parental permission or have pro‐
posed legislation for restricting the use of tanning beds for minors. The use of tanning salons
by adolescents did not decline from 1998 to 2004, even though more states restricted use by
minors (Cokkinides et al., 2009), which suggests that these partial restrictions may not be
effective. Predictors of using tanning salons for women were residing in the Midwest and the
South and using spray tan products, while men who lived in metropolitan areas were more
likely to visit tanning salons.
Figure 5. Relative risk of melanoma associated with exposure to indoor tanning. Results of seven studies and overall
estimate. Values higher than 1.0 indicate heightened risk of melanoma. Modified from (Schulman and Fisher, 2009).
2.5. PUVA therapy
Ultraviolet A radiation therapy (PUVA) is a common and effective treatment for psoriasis that
was first introduced in the 1970s. Since UVA exposure from the sun and artificial sources like
tanning beds is a clear risk for melanoma, there is concern that PUVA therapy may predispose
to malignancies including melanoma. One large cohort study that followed patients for 20
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years found that there was a 10-fold increase in the incidence of invasive melanoma in patients
who had received PUVA therapy versus age matched controls (Stern, 2001). Increased risk
began at 15 years post-PUVA therapy exposure, and there was a stronger association with
patients exposed to higher doses of PUVA therapy, more treatments (greater than 250), and in
patients with fair skin. Thus, limiting exposure to PUVA to minimal doses and carefully
selecting appropriate patients for the treatment can maximize the effectiveness of this treat‐
ment and minimize the risks. Patients who receive PUVA therapy should be carefully followed
to facilitate early detection of melanoma and other skin cancers.
2.6. Skin pigmentation
Although individuals from any race or skin pigmentation group can be affected by melanoma,
risk of disease is much higher in fair-skinned persons (Fig. 6) (Beral et al., 1983; Rees and Healy,
1997; Sturm, 2002). Created by Dr. Thomas Fitzpatrick in 1975, the Fitzpatrick scale is com‐
monly used to describe skin tone and resultant UV sensitivity (Draelos, 2011). Skin complexion
is mainly determined by the amount of black melanin in the epidermis. This pigment, called
eumelanin, is a potent blocker of UV radiation. Thus the more eumelanin in the skin, the less
UV penetrates into the deep layers of the epidermis, and the less UV-mediated mutagenesis
will occur. Risk of sunburn is also heavily influenced by epidermal eumelanin content. In fair-
skinned individuals with low Fitzpatrick skin types, it takes a much lower dose of UV to induce
inflammation. The amount of UV needed to cause a sunburn is termed the “minimal eryth‐
ematous dose” (MED), and a lower MED correlates with low levels of epidermal eumelanin
and a higher risk of melanoma (Ravnbak et al., 2010) (Fig. 7). Thus, risk of melanoma for
Caucasian males and females is 31.6 and 19.9 per 100,000 respectively, while risk for African
American males and females is only 1.1 and 0.9 per 100,000 in comparison (Ekwueme et al.,
2011; Park et al., 2012).
Figure 6. Racial Disparity in Melanoma Incidence (US). Incidence rates based on NCI SEER data. Note that in gener‐
al, the darker a race’s average skin tone, the lower their incidence of melanoma, irrespective of gender.
Melanoma — Epidemiology, Genetics and Risk Factors
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Figure 7. Melanoma risk varies according to skin complexion. Skin complexion can be estimated by the Fitzpatrick
scale wherein the higher the number, the more deeply melanized and pigmented the skin is. Fair-skinned individuals
are much more UV sensitive and tend to burn rather than tan after UV exposure. Melanoma risk is highest in fair-skin‐
ned individuals.
2.7. Nevi
The majority of melanomas arise out of pre-existing moles (nevi), therefore the more nevi a
person has, the higher the likelihood that a melanoma may develop (Grob et al., 1990; Newton-
Bishop et al., 2010). One study found a seven-fold increased relative risk for melanoma if a
patient has more than one hundred nevi (Gandini et al., 2005). Most patients, however, do a
poor job in estimating their own mole counts (Melia et al., 2001), and a patient’s self assessment
of nevus count should not be relied upon in lieu of a full skin exam for melanoma screening
(Psaty et al., 2010). Despite the link between nevi and melanoma, risk of any given mole
progressing to malignancy is very low (Metcalf and Maize, 1985; Halpern et al., 1993). One
study estimated the 60 year risk of malignant transformation to be 1:11,000 for an individual
nevus on a 20 year-old woman (Tsao et al., 2003).
A molecular link between benign nevi and malignant melanoma was established in 2003 when
Pollock and coworkers reported that a gain of function mutation in the BRAF gene was
common to the majority of benign nevi and melanomas (Pollock et al., 2003). Specifically, the
V599E amino-acid substitution in BRAF results in enhanced MAPkinase signaling which
stimulates melanocytes to proliferate. Clearly other genetic and/or epigenetic cellular events,
such as loss of the tumor suppressor p16, are required for full malignant transformation, as
BRAF mutation is sufficient for nevi formation but not melanomagenesis.
Congenital melanocytic nevi are pigmented lesions found on individuals at birth (Zaal et al.,
2005; Krengel et al., 2006). Those that are particularly large (>20 cm in diameter) seem partic‐
ularly prone to malignant transformation, and are associated with a lifetime melanoma risk of
approximately 10% (Krengel et al., 2006). Smaller congenital melanocytic nevi have a signifi‐
cantly lower risk of malignant degeneration. Given their relatively high malignant potential,
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large congenital melanocytic nevi warrant consideration for prophylactic excision (Psaty et al.,
2010) preferably during childhood, since up to 70% of melanomas associated with congenital
melanocytic nevi occur by the individual’s tenth year (Marghoob et al., 2006).
Atypical Mole Syndrome (also referred to as Dysplastic Nevus Syndrome or Familial Atypical
Multiple-Mole Melanoma Syndrome) has emerged as one of the most significant risk factors
for the development of melanoma (Carey et al., 1994; Slade et al., 1995; Seykora and Elder,
1996). In the general population, dysplastic nevi are relatively common: found on 2-8% of
Caucasians especially among those under 30 (Naeyaert and Brochez, 2003). A combination of
both UV exposure and genetic susceptibility is believed to contribute to dysplastic nevi
formation (Naeyaert and Brochez, 2003). Atypical Mole Syndrome is an important melanoma
risk factor (Halpern et al., 1993); individual melanoma risk approaches 82% in affected
individuals by the age of 72 (Tucker et al., 1993).
2.8. Chemical exposure and occupational risk
Geographic discrepancy in melanoma incidence may be influenced by factors other than UV
exposure and skin pigmentation (Fortes and de Vries, 2008). A number of environmental and
occupational substances have been linked to development of malignant melanoma including
heavy metals, polycyclic aromatic hydrocarbons (PAHs) and benzene (Ingram, 1992; Vinceti
et al., 2005; Meyskens and Yang, 2011 ). As a result of working around many of these chemicals,
petroleum workers, for example, have been reported to have up to an eight-fold increased risk
of melanoma (Magnani et al., 1987). Polyvinyl chloride (PVC), a substance used widely in the
clothing and chemical industries, is also linked to increased risk of melanoma (Lundberg et
al., 1993; Langard et al., 2000). Printers and lithographers, through their exposure to PAH and
benzene solvents, have up to a 4.6-fold increased risk of disease (McLaughlin et al., 1988).
Ionizing radiation exposure, as might occur from medical radiation exposure or atomic energy
occupational exposure has also been linked to melanoma risk (Fink and Bates, 2005; Lie et al.,
2008; Korcum et al., 2009). Pesticide exposure was reported to almost triple melanoma risk
(Burkhart and Burkhart, 2000). Clearly a better understanding of occupational risk factors,
especially when coupled to UV risk, is needed to guide more targeted public health efforts for
the prevention of melanoma (Fortes and de Vries, 2008).
2.9. Immunodeficiency
Immunodeficiency, either from inherited defects in cell-mediated immunity or from infection-
associated immunosuppression (e.g. AIDS) clearly predisposes individuals for the develop‐
ment of melanoma (Silverberg et al., 2011). Furthermore, with the increasing prevalence of
autoimmune disorders and solid organ transplantation requiring medical restraint of native
immune function, iatrogenic immunosupression is becoming an increasingly important risk
factor for malignancy (DePry et al., 2011). The number of individuals in the US living with
solid organ transplant has more than doubled since 1998 to more than 225,000 individuals
(Sullivan et al., 2012). Although immunosuppressive agents expose patients to increased risk
for a large number of malignancies, cutaneous cancer risk is particularly affected (Engels et
al., 2011), and skin cancers in immunsuppressed patients may behave more aggressively than
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those in immunocompetent persons (Brewer et al., 2011). Cancer patients treated with
chemotherapy also have a higher incidence of melanoma, presumably either because of the
mutagenic effects of chemotherapy on melanocytes or perhaps through immunosuppression
(Smith et al., 1993). Therefore, solid tumor transplant patients, persons with inborn or acquired
deficiencies of T cell function and anyone with a current or past pharmacologic history of
chemotherapy or immunosuppressive medications should be advised to practice UV-avoiding
strategies and be regularly screened for cutaneous malignancies.
3. Genetic factors
While UV exposure is the most significant environmental risk factor for melanoma, there are
several genes that when mutated clearly influence melanoma risk (Meyle and Guldberg,
2009; Nelson and Tsao, 2009; Ward et al., 2012). These genes have been identified largely
through studying melanoma-prone families or individuals with extraordinary UV sensitivity
or melanoma predisposition. Some of these genetic defects cause bone fide familial cancer
syndromes, characterized by heritable predisposition to one or more types of malignancy. Each
cancer syndrome is associated with unique cancer risk. Clinical “clues” to melanoma familial
cancer syndromes include: melanomas diagnosed at a young age (e.g. below forty years of
age), multiple primary melanomas diagnosed in the same person over time, multiple family
members affected by melanoma, and extreme UV sensitivity (D'Orazio 2010). It is estimated
that up to twelve percent of patients diagnosed with melanoma will have a positive family
history of melanoma, yet even among this group, there is often no identifiable melanoma
susceptibility gene (Gandini et al., 2005). Many of these melanoma susceptibility genes can
portend risk vastly exceeding that of the general population (Udayakumar and Tsao, 2009).
3.1. Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A)
The familial atypical multiple mole and melanoma (FAMMM) syndrome was first described
in two families in which affected individuals harbored more than one hundred dysplastic nevi
and had a lifetime cumulative incidence of melanoma approaching one hundred percent
(Clark et al., 1978; Lynch et al., 1978). This syndrome, also called “dysplastic nevus syndrome”
was associated with many of the features of a familial cancer syndrome, including melanomas
at young ages (median age of 33 years in one study) (Goldstein et al., 1994). Heterozygous loss
of CDKN2A function is associated with roughly 40% of cases of familial melanoma (Kamb et
al., 1994; Holland et al., 1995)
Linkage studies performed in melanoma pedigrees identified loss of heterozygosity in the
chromosome 9p21 region (Fountain et al., 1992). Later, the cyclin-dependent kinase inhibitor
2A gene was identified through positional cloning to be the tumor suppressor on 9p21 that
was mutated in many melanoma-prone families (Kamb et al., 1994; Weaver-Feldhaus et al.,
1994). Interestingly, affected individuals were not only at higher risk of malignant melanoma
of the skin, but also for central nervous system gliomas, lung cancers and leukemias (Nobori
et al., 1994). CDKN2A actually encodes two distinct tumor suppressor proteins- p16 and
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p14ARF that are transcribed in alternate reading frames directed through the use of alternative
first exons (Chin et al., 1998; Sharpless and DePinho, 1999; Sharpless and Chin, 2003). p16/
INK4a is produced from a transcript generated from exons 1α, 2 and 3, and p14/Arf is generated
in an alternative reading frame, from a transcript of exons 1β, 2 and 3 (Udayakumar and Tsao,
2009). The majority of melanoma-associated mutations impacting exon 1β, which is specific
for p16INK4a. Most germline mutations in CDKN2A found to contribute to melanoma
susceptibility are loss-of-function missense or nonsense mutations of p16 (Goldstein et al.,
2006; Goldstein et al., 2007).
The p16 tumor suppressor protein acts to regulate cell proliferation at the G1/S cell cycle
checkpoint by inhibiting the cyclin-dependent kinases CDK4 and CDK6 to prevent entry into
S-phase of the cell cycle (Serrano et al., 1993; Ohtani et al., 2001). Cyclin-dependent kinases in
complex with cyclin D function jointly to inactivate the retinoblastoma (RB1) by phosphory‐
lation. Once phosphorylated, RB1 is released from the transcription factor E2F-1, thereby
permitting E2F-dependent transcription of genes that propel cells into proliferation. By
binding to and inhibiting CDK4, p16 acts to prevent cell cycle progression, and when p16
function is lost, cells lose regulatory control over CDK/cyclin activity and proceed into
unregulated cell division (Bartkova et al., 1996; Chin et al., 1998; Liggett and Sidransky, 1998).
As with many other tumor suppressor genes, it is thought that inactivation or underexpression
of both alleles of CDKN2A may be required for a cancer phenotype to emerge (the “two-hit”
hypothesis) (Knudson, 1996; Tomlinson et al., 2001; Payne and Kemp, 2005). Thus individuals
with inherited loss of one copy of p16 are at risk for p16-dependent malignancies such as
melanoma (Ranade et al., 1995), with cancers developing only if the remaining p16 allele is
inactivated to a sufficient extent either through mutation or epigenetic inactivation (Berger et
al., 2011).
3.2. Cyclin-Dependent Kinase 4 (CDK4)
Several melanoma-prone kindreds have been discovered who carry mutations not in
CDKN2A, but in its target- cyclin-dependent kinase 4 (CDK4) (Zuo et al., 1996; Soufir et al.,
1998; Goldstein et al., 2000). Unlike CDKN2A whose p16 protein product acts as a tumor
suppressor by negatively regulating melanocyte proliferation, CDK4 is an oncogene whose
activity enhances cell division. The gain-of-function mutations in CDK4 melanoma-prone
families typically result in amino acid changes that render the CDK4 enzyme insensitive to
p16 inhibition, thereby resulting in a functional p16 null phenotype (Zuo et al., 1996; Newton
Bishop et al., 1999; Goldstein et al., 2000).
3.3. Xeroderma Pigmentosum (XP) genes
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder of the nucleotide excision
DNA repair (NER) pathway caused by homozygous deficiency of any one of at least eight
genes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XPV) that work in complex to repair bulky
DNA lesions such as mutagenic DNA photoproducts caused by UV radiation (Leibeling et al.,
2006) (Fig. 8). NER functions by recruiting a protein complex known as XPC-hHR23B to UV-
induced photoproducts in the DNA, with XPE aiding lesion verification. TFIIH, a transcription
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factor containing multiple enzymes including XPA, XPB and XPD then unwind the DNA in
the vicinity of the damaged bases, and then two endonucleases XPF-ERCC1 and XPG incise
the lesion on either side of the photodamage to release the damaged DNA section. Finally,
using the undamaged strand as a template to ensure fidelity, DNA polymerase, PCNA, RFC
and DNA ligase I act in concert to synthesize and ligate the new DNA fragment. In this manner,
the NER pathway is the cell’s major defense against DNA damage and if defective, UV-induced
mutations accumulate in the genome.
Figure 8. UV-induced cyclobutane dimers- structure (A) and repair by the Nucleotide Excision DNA Repair
(NER) pathway (B). The NER pathway is mediated by at least eight enzymes that work together to identify bulky DNA
lesions that distort the structure of the double helix, excise the damaged portion and replace the excised region by
DNA synthesis directed by the complementary strand. Homozygous deficiency in any one of the NER enzymes leads to
the clinical condition known as Xeroderma Pigmentosum (XP). Please note that although not shown, NER can also be
initiated in actively transcribed regions of the genome by involvement of the Cockayne syndrome proteins A and B.
As a result of the inability of the skin to recover after UV exposure, intense sun sensitivity is
one of the first manifestations of XP. Estimated incidences vary from 1 in 20,000 in Japan to 1
in 250,000 in the US (Robbins et al., 1974). Beginning in the first or second year of life, UV-
exposed skin (e.g. on the face and arms) develops areas of hypo- or hyper-pigmented macules,
telangiectasias and atrophy, all signs of chronic sun exposure that normally take decades to
develop. Premalignant lesions such as actinic keratoses develop, and typically malignancies
such as basal cell carcinomas, squamous cell carcinomas and melanomas start appearing by
the age of ten years. XP patients have more than a thousand-fold increased risk of skin cancer
and develop malignancies decades earlier than unaffected patients (Van Patter and Drum‐
mond, 1953; Lynch et al., 1981; Cleaver, 2005; Jen et al., 2009; Rao et al., 2009; Wang et al.,
2009). Melanomas isolated from XP patients clearly bear evidence of “UV signature muta‐
tions”, lending support to the concept that defective repair of UV-induced photodimers
underlies carcinogenesis of melanocytes (Takebe et al., 1989; Sato et al., 1993). Beside skin
cancer, XP patients suffer a 20-fold increased risk of other malignancies including lung cancer,
gastric carcinoma and brain cancer, perhaps reflecting the importance of NER in the repair of
damage produced by agents other than UV. Overall, approximately 70% of persons with XP
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die by the age of 40 years from cancer. Currently there is no accepted therapy for treating XP
other than avoidance of sunlight and careful surveillance and local control of pre-malignant
or malignant lesions as they appear. The use of topical DNA repair enzymes such asT4
endonuclease V which cleaves UV-induced photolesions(Cafardi and Elmets, 2008) and novel
UV-protective strategies such as the pharmacologic induction of cutaneous melanin levels
which block penetration of UV radiation (D'Orazio et al., 2006) are being developed and may
hold great promise for these exceptionally UV-sensitive individuals.
Intriguingly, although the homozygous condition known as XP reveals much about the
importance of the NER pathway in melanoma resistance and ability of UV radiation to fuel
melanomagenesis, evidence is accumulating that polymorphisms in NER enzymes in the
general (non-XP) population may influence melanoma risk. For example, several studies have
found an association between polymorphisms in certain NER enzymes and melanoma
including XPD (Tomescu et al., 2001; Mocellin et al., 2009), XPC and XPF (Winsey et al., 2000;
Baccarelli et al., 2004; Blankenburg et al., 2005; Debniak et al., 2006). Some groups have posited
that multiple NER variants in a single individual may be required to influence melanoma
susceptibility (Li et al., 2006).
3.4. Melanocortin 1 Receptor (MC1R)
The MC1R is a seven transmembrane Gs-coupled protein that, when bound by melanocyte
stimulating hormone (MSH), activates adenylyl cyclase and cAMP generation (Fig. 9). This
cAMP second messenger signaling leads to activation of the protein kinase A (PKA) cascade
which, in turn, leads to up-regulation of the MITF and CREB transcription factors that together
induce expression of melanin biosynthetic enzymes such as tyrosinase and dopachrome
tautomerase (Yasumoto et al., 1994; Bertolotto et al., 1996; Fang and Setaluri, 1999). In this
manner, MC1R signaling enhances the production and export of melanin by melanocytes to
maturing epidermal keratinocytes, thereby controlling the melanin levels and innate UV
resistance of the skin (Fig. 9). When MC1R signaling is defective, then melanocytes alter the
type and amount of melanin they manufacture. Specifically, a red/blonde sulfated pigment
known as pheomelanin is produced rather than the brown/black eumelanin species. Pheome‐
lanin is a much poorer blocker of UV photons and may even contribute to oxidative damage
within melanocytes, itself a possible mutagenic mechanism.
Loss-of-function polymorphisms have been identified in MC1R, with the vast majority of
allelic variation occurring in European and Asian populations. The most prevalent MC1R
mutations (D84E, R142H, R151C, R160W, and D294H) are known as the “RHC” (red hair color)
alleles because of the association with a blonde/red hair color, freckling and tendency to burn
rather than tan after UV exposure (Scherer and Kumar, 2010). RHC MC1R alleles are also
associated with a relatively high lifetime risk of melanoma (increased odds ratio of 2.40 in one
study) (Williams et al., 2011). MC1R variants may also modify other melanoma-relevant alleles
(van der Velden et al., 2001; Demenais et al., 2010; Kanetsky et al., 2010; Kricker et al., 2010).
In a Australian cohort, for example, co-inheritance of either the MC1R variants R151C, R160W
or D294H with CDKN2A mutations and decreased latency for melanoma by approximately
20 years (Box et al., 2001). A more recent study found that MC1R variants significantly
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increased penetrance and lowered the age of melanoma diagnosis in people with CDKN2A
mutations, (Fargnoli et al., 2010).
In addition to its role in skin melanization, MC1R may influence melanoma development by
non-pigmentary pathways as well (Matichard et al., 2004; Goldstein et al., 2005). Specifically,
we and others have found that MC1R signaling influences the ability of melanocytes to recover
from UV-induced DNA damage (Hauser et al., 2006; Abdel-Malek et al., 2009; Song et al.,
2009). MC1R signaling directly enhances NER in melanocytes, and studies are underway to
discover the molecular mechanisms linking MC1R signaling to the NER DNA damage repair
pathway. Overall, there is much evidence placing MC1R as a “master regulator” of melanocyte
UV physiologic responses.
Figure 9. The central role of the melanocortin 1 receptor (MC1R) in the epidermal response to UV radiation. UV-
induced cellular and DNA damage to epidermal keratinocytes induces activation of the global damage response pro‐
tein p53, which mediates transcriptional activation of the pro-opiomelanocortin (POMC) gene. The POMC gene
encodes a propeptide that is cleaved into melanocyte stimulating hormone (MSH) along with β-endorphin and adre‐
nocorticotropic hormone (ACTH). MSH secreted from UV-exposed keratinocytes then is hypothesized to bind melano‐
cortin 1 receptors (MC1R) on melanocytes in the basal epidermis. MSH binding induces generation of the second
messenger cAMP via MC1R-mediated activation of adenylate cyclase in melanocytes. Generation of cAMP triggers a
number of downstream events including activation of the protein kinase A signaling pathway and up-regulation of
the cAMP responsive binding element (CREB) and microphthalmia (Mitf) transcription factors. CREB and Mitf induce
melanin production through transcriptional up-regulation of melanin biosynthetic enzymes. Thus, MSH-MC1R signal‐
ing leads to enhanced pigment synthesis and subsequent transfer of melanin to epidermal keratinocytes. In this man‐
ner, the skin is more protected against subsequent UV exposure. MSH-MC1R signaling may also enhance nucleotide
excision repair (NER) in melanocytes, which would enhance recovery from UV damage.
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3.5. Microphthalmia (MITF)
Mitf is a myc-like transcription factor that is critical to melanocyte development and survival
(Levy et al., 2006). Defective Mitf leads to disorders of melanocyte function and pigmentation
(Fisher, 2000; Goding, 2000; Widlund and Fisher, 2003; Steingrimsson et al., 2004). In humans,
for example, Waardenburg syndrome type 2 is caused by inactivating mutations of Mitf, and
is characterized by pigmentary defects due to the congenital absence of melanocytes in distinct
anatomic locations (hair, skin eyes) (Hughes et al., 1994; Tassabehji et al., 1994). Mitf Immu‐
nohistochemical staining has long been used to identify surgical tumor isolates as melanomas
(King et al., 1999; Salti et al., 2000), but its oncogenic contribution to melanoma wasn’t realized
until Garraway and colleagues reported Mitf to be amplified in a subset of melanomas,
particularly in aggressive disease (Garraway et al., 2005). Mitf may be amplified in up to 20%
of metastatic melanomas and is associated with activation of the hypoxia inducible factor
(HIF1A) pathway (Busca et al., 2005; Cheli et al., 2012) and reduced patient survival (Ugurel
et al., 2007).
More recently, melanoma predisposition due to point mutations of Mitf (rather than gene
amplification) were described. The E318K Mitf variant correlated with a positive melanoma
family history, multiple primary melanomas or risk of melanoma and renal cell carcinoma in
the same patient. Mechanistically, it is thought that the E318K Mitf variant leads to gain-of-
function in Mitf by impairing its SUMO-mediated clearance (Bertolotto et al., 2011; Yokoyama
et al., 2011). Thus whether by increased gene doseage or increased protein stability, Mitf seems
to be a relevant melanoma oncogene, and current research efforts are attempting to devise
pharmacologic targeting of MITF (Flaherty et al., 2010).
4. Conclusions
An explosion of information regarding the molecular pathways involved in melanoma
development has been witnessed in the last several years. The MAPkinase cascade, for
example, has emerged as a critical oncogenic pathway that drives the majority of cases of
melanoma. Gain of function mutations in BRAF, most notably the V600E point mutation that
results in unregulated BRAF signaling, have been described in at least half of all cutaneous
melanomas (Davies et al., 2002; Pollock and Meltzer, 2002; Pollock et al., 2003). Oncogenic
BRAF mutations lead to constitutive activation of kinase activity of BRAF, providing contin‐
uous growth signals in the absence of extracellular stimuli (Nikolaou et al., 2012). In many
melanomas in which BRAF has not been mutated or in melanomas treated with BRAF
inhibitors, N-Ras oncogene upregulation has been observed, leading again to increased
signaling through the MAPkinase cascade (Padua et al., 1984; van 't Veer et al., 1989; Ball et
al., 1994; Carr and Mackie, 1994; Wagner et al., 1995; Goydos et al., 2005; Nazarian et al.,
2010). Though targeted inhibition of the MAPkinase signaling pathway has led to significant
advances in the treatment of melanoma (Flaherty et al., 2010; Falchook et al., 2012), to date,
somatic inheritance of MAPkinase activating mutations leading to melanoma predisposition,
have not been reported.
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The incidence of melanoma has risen at an alarming rate over the last several decades. The
reasons for this increase are unclear, but probably represent the confluence of a variety of
environmental and inherited risk factors. Though significant progress has been made over the
last several years in immunotherapy (Hodi et al., 2010; Kaplan, 2011; Wilson, 2011) and
targeted kinase inhibition against melanoma (Flaherty et al., 2010; Chapman et al., 2011;
Flaherty et al., 2012; Sosman et al., 2012), clearly it would be better to prevent development of
disease in the first place. As our understanding of the molecular mechanisms that underlie the
malignant degeneration of melanocytes expands, so hopefully will our ability to develop
rational interventions to prevent the development of melanoma.
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